Show simple item record

Disposition of quinapril and quinaprilat in the isolated perfused rat kidney

dc.contributor.authorKugler, Alan R.en_US
dc.contributor.authorOlson, Stephen C.en_US
dc.contributor.authorSmith, David E.en_US
dc.date.accessioned2006-09-11T15:36:48Z
dc.date.available2006-09-11T15:36:48Z
dc.date.issued1995-06en_US
dc.identifier.citationKugler, Alan R.; Olson, Stephen C.; Smith, David E.; (1995). "Disposition of quinapril and quinaprilat in the isolated perfused rat kidney." Journal of Pharmacokinetics and Biopharmaceutics 23(3): 287-305. <http://hdl.handle.net/2027.42/45050>en_US
dc.identifier.issn0090-466Xen_US
dc.identifier.issn1573-8744en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45050
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8834197&dopt=citationen_US
dc.description.abstractAn isolated perfused rat kidney model was used to probe the renal disposition of quinapril and quinaprilat after separate administration of each drug species. Control studies were performed with drug-free perfusate ( n=8 ) and perfusate containing quinapril ( n=9 ) quinaprilat ( n=7 ) at initial drug concentrations of 1000 ng/ml (including corresponding tracer levels of tritiated drug). Physiologic parameters were within the normal range of values for this technique and were stable for the duration of each experiment. Quinapril and quinaprilat concentrations were determined in perfusate, urine, and perfusate ultrafiltrate using a specific and sensitive reversed-phase HPLC procedure with radiochemical detection, coupled to liquid scintillation spectrometry. Perfusate protein binding was determined using an ultrafiltration method at 37°C. The total renal learance of quinapril ( CLr ) was calculated as Dose/AUC (0-∞), and is represented by the sum of its urinary and metabolic clearances. The urinary clearances ( CLe ) of quinapril and quinaprilat were calculated as urinary excretion rate divided by midpoint perfusate concentration for each respective species. Of the total renal clearance for quinapril ( CLr =4.49 ml/min), less than 0.1% was cleared as unchanged drug ( CLe =0.004 ml/min); over 99% of the drug was cleared as quinaprilat formed in the kidney. The clearance ratio of quinapril [ CR=CLr/(fu·GFR )] was 41.0, a value representing extensive tubular secretion into the renal cells. Following quinaprilat administration, the clearance ratio of metabolite [ CR=CLe/(fu β GFR) ] was 3.85, indicating a net secretion process for renal elimination.en_US
dc.format.extent1019385 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherQuinaprilen_US
dc.subject.otherClearanceen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherPharmacyen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherVeterinary Medicineen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherQuinaprilaten_US
dc.subject.otherIsolated Perfused Rat Kidneyen_US
dc.subject.otherRenal Dispositionen_US
dc.titleDisposition of quinapril and quinaprilat in the isolated perfused rat kidneyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, 3705 Upjohn Center, The University of Michigan, 48109-0504, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 48106-1047, Ann Arbor, Michigan; College of Pharmacy and Upjohn Center for Clinical Pharmacology, 3705 Upjohn Center, The University of Michigan, 48109-0504, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 48106-1047, Ann Arbor, Michiganen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid8834197en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45050/1/10928_2006_Article_BF02354286.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF02354286en_US
dc.identifier.sourceJournal of Pharmacokinetics and Biopharmaceuticsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.